Arie S. Belldegrun is an entrepreneur and businessperson who founded 6 companies, among them: Kite Pharma, Inc., Allogene Therapeutics, Inc. and Agensys, Inc. and who has been at the head of 16 different companies. Presently, he holds the position of Chairman & Partner at Two River Group Holdings LLC, Chairman for Two River Group Management LLC, Chairman at Bellco Capital LLC (which he founded in 2003), Chairman at Two Rivers Consulting Corp., Chairman for UroGen Pharma Ltd., Chairman & Partner at Two River Consulting LLC, Executive Chairman of Allogene Therapeutics, Inc. (which he founded in 2017), Chairman of Kronos Bio, Inc., Co-Chairman at Breakthrough Properties LLC, Senior Managing Director at VV Manager LLC (which he founded in 2017), Senior Managing Director at Vida Ventures LLC (which he founded in 2017) (a subsidiary of VV Manager LLC) and Chairman of Technology Assessment Group. Arie S. Belldegrun is also Director & Professor at UCLA Institute of Urologic Oncology, Head-Urologic Oncology Division at David Geffen School of Medicine and Senior Managing Director at Vida Ventures LLC (he founded the company in 2017) and on the board of 5 other companies. Dr. Belldegrun previously was Chairman of Arno Therapeutics, Inc. and Non-Executive Chairman at Arno Therapeutics, Inc. (a subsidiary of Arno Therapeutics, Inc.), Chairman, President & Chief Executive Officer at Equinor ASA, Director at Agensys, Inc. (he founded the company in 1997), Executive Chairman, President & CEO at Kite Pharma, Inc. (he founded the company in 2009), Chairman-Molecular Biological Technology Committee at American Urological Association Education & Research, Inc., Researcher at National Cancer Institute and Member of Los Angeles Economy & Jobs Committee. Arie S. Belldegrun received a doctorate from The Hebrew University Hadassah Medical School and a graduate degree from Weizmann Institute of Science.